Modified BEAM conditioning regimen in patients with hodgkin and non-hodgkin lymphomas

Experimental and Clinical Transplantation

Volumn 10, Issue 6, 2012, Pages 622-

  Neto, Abrahão Elias Hallack ^a,b   dos Santos, Kelli Borges ^b   Atalla, Angelo ^a,b  

^a School of Medicine   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Conditioning; Hematopoietic stem cell transplant; Lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; LOMUSTINE; MELPHALAN;

ACUTE KIDNEY FAILURE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; DEATH; EVENT FREE SURVIVAL; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LETTER; NONHODGKIN LYMPHOMA; REMISSION; SEPSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LOMUSTINE; LYMPHOMA, NON-HODGKIN; MELPHALAN;

EID: 84871316215     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0091     Document Type: Letter

References (4)

1. Ramzi M, Mohamadian M, Vojdani R, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10(2):163-167.
2. Chao NJ, Kastrissios H, Long GD, et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer. 1995;75(6):1354-1359.
3. Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant. 2007;39(1):41-47.
4. Hather GJ, Mackey H. Some notable properties of the standard oncology Phase I design. J Biopharm Stat. 2009;19(3):543-555.